Baseline characteristics stratified by pre-interventional reperfusion
| Variables | Total (n=396) | Previous cs-eTICI <2a (n=369) | Previous cs-eTICI ≥2a (n=27) | P value | |||
| No* | No* | No* | |||||
| Treatment arm (n (%)) | 396 | 369 | 27 | 0.015 | |||
| IV t-PA + MT | 200 (50.5) | 180 (48.8) | 20 (74.1) | ||||
| MT only | 196 (49.5) | 189 (51.2) | 7 (25.9) | ||||
| Age at inclusion (years) (median (IQR)) | 396 | 72 (64–81) | 369 | 72 (64–81) | 27 | 70 (62–83) | 0.75 |
| Women (n (%)) | 396 | 204 (51.5) | 369 | 188 (50.9) | 27 | 16 (59.3) | 0.43 |
| NIHSS (median (IQR)) | 396 | 17 (13–20) | 369 | 17 (13–20) | 27 | 18 (13–21) | 0.67 |
| Pre-stroke mRS (n (%)) | 396 | 369 | 27 | 0.80 | |||
| 0 | 336 (84.8) | 312 (84.6) | 24 (88.9) | ||||
| 1 | 59 (14.9) | 56 (15.2) | 3 (11.1) | ||||
| 4 | 1 (0.3) | 1 (0.3) | 0 (0.0) | ||||
| Weight (kg) (median (IQR)) | 371 | 75 (65–85) | 344 | 75 (65–85) | 27 | 70 (66–85) | 0.96 |
| Systolic blood pressure (mm Hg) (median (IQR)) | 391 | 147 (130–162) | 364 | 147 (130–162) | 27 | 147 (131–163) | 0.94 |
| Diastolic blood pressure (mm Hg) (median (IQR)) | 388 | 80 (70–90) | 361 | 80 (70–90) | 27 | 76 (69–89) | 0.43 |
| Heart rate (beat/min) (median (IQR)) | 385 | 74 (64–87) | 359 | 74 (64–88) | 26 | 75 (65–81) | 0.78 |
| Risk factors (n (%)) | |||||||
| Previous ischemic stroke | 382 | 39 (9.8) | 357 | 36 (9.8) | 25 | 3 (11.1) | 0.74 |
| Previous transient ischemic attack | 377 | 20 (5.1) | 351 | 20 (5.4) | 26 | 0 (0.0) | 0.38 |
| History of hypertension | 386 | 232 (58.6) | 359 | 211 (57.2) | 27 | 21 (77.8) | 0.043 |
| History of atrial fibrillation | 375 | 37 (9.3) | 349 | 35 (9.5) | 26 | 2 (7.4) | 1.00 |
| History of hypercholesterolemia | 375 | 126 (31.8) | 349 | 116 (31.4) | 26 | 10 (37.0) | 0.53 |
| Previous intracerebral hemorrhage | 385 | 2 (0.5) | 359 | 2 (0.5) | 26 | 0 (0.0) | 1.00 |
| Previous myocardial infarction | 378 | 41 (10.4) | 352 | 39 (10.6) | 26 | 2 (7.4) | 1.00 |
| Medication (n (%)) | |||||||
| Warfarin or other anticoagulant | 396 | 15 (3.8) | 369 | 14 (3.8) | 27 | 1 (3.7) | 1.00 |
| Aspirin | 396 | 102 (25.8) | 369 | 96 (26.0) | 27 | 6 (22.2) | 0.82 |
| Statin or other lipid lowering agent | 396 | 115 (29.0) | 369 | 105 (28.5) | 27 | 10 (37.0) | 0.38 |
| Laboratory values | |||||||
| Blood glucose level (mmol/L) (median (IQR)) | 373 | 6.5 (5.8–7.5) | 348 | 6.5 (5.8–7.5) | 25 | 6.8 (6.0–7.8) | 0.50 |
| International normalized ratio (median (IQR)) | 309 | 1.0 (1.0–1.1) | 290 | 1.0 (1.0–1.1) | 19 | 1.1 (1.0–1.1) | 0.28 |
| Platelet count ×10e9(g/L) (median (IQR)) | 393 | 226 (188–272) | 366 | 226 (187–270) | 27 | 238 (193–319) | 0.28 |
| Hemoglobin (g/L) (median (IQR)) | 396 | 137 (125–146) | 369 | 137 (125–146) | 27 | 135 (118–146) | 0.50 |
| Glomerular filtration rate (mL/min) (median (IQR)) | 396 | 76 (62–90) | 369 | 76 (62–90) | 27 | 70 (55–87) | 0.43 |
| Baseline imaging (n (%)) | 396 | 369 | 27 | 0.38 | |||
| CT | 195 (49.2) | 185 (50.1) | 10 (37.0) | ||||
| MRI | 198 (50.0) | 181 (49.1) | 17 (63.0) | ||||
| Both | 3 (0.8) | 3 (0.8) | 0 (0.0) | ||||
| ASPECTS (core lab) (median (IQR)) | 396 | 8.0 (7.0–9.0) | 369 | 8.0 (7.0–9.0) | 27 | 8.0 (7.0–9.0) | 0.94 |
| Baseline intracranial occlusion site (n (%)) | 396 | 369 | 27 | 0.77 | |||
| ICA | 113 (28.5) | 107 (28.9) | 6 (22.2) | ||||
| ICA and M1 | 2 (0.5) | 2 (0.5) | 0 (0.0) | ||||
| M1 | 259 (65.4) | 240 (65.0) | 19 (70.4) | ||||
| M2 | 22 (5.6) | 20 (5.4) | 2 (7.4) | ||||
| Distal occlusion sites (n (%)) | 396 | 369 | 27 | 0.15 | |||
| No | 257 (64.9) | 243 (65.9) | 14 (51.9) | ||||
| Yes | 139 (35.1) | 126 (34.1) | 13 (48.1) | ||||
| Tandem lesion (n (%)) | 396 | 63 (15.9) | 369 | 62 (16.8) | 27 | 1 (3.7) | 0.10 |
| Stroke etiology (n (%)) | 396 | 369 | 27 | 0.74 | |||
| Large artery atherosclerosis | 68 (17.2) | 63 (17.1) | 5 (18.5) | ||||
| Cardioembolism | 149 (37.6) | 137 (37.1) | 12 (44.4) | ||||
| Other determined etiology | 18 (4.5) | 18 (4.9) | 0 (0.0) | ||||
| Undetermined etiology | 161 (40.7) | 151 (40.9) | 10 (37.0) | ||||
| Timelines | |||||||
| Time from stroke onset to randomization (min) (median (IQR)) | 396 | 130 (101–170) | 369 | 128 (100–168) | 27 | 144 (122–181) | 0.08 |
| Time from symptom onset to start of IV t-PA (min) (median (IQR)) | 200 | 145 (112–181) | 180 | 143 (110–176) | 20 | 160 (130–190) | 0.08 |
| Time from arrival at emergency department to IV t-PA (min) (median (IQR)) | 200 | 55 (38–72) | 180 | 55 (37–73) | 20 | 61 (46–71) | 0.39 |
| Time from arrival at emergency department to groin puncture (min) (median (IQR)) | 396 | 78 (62–95) | 369 | 76 (61–94) | 27 | 83 (73–102) | 0.08 |
| Time from randomization to groin puncture (min) (median (IQR)) | 396 | 28 (20–39) | 369 | 28 (20–38) | 27 | 30 (22–46) | 0.30 |
| Time from start of intravenous alteplase to groin puncture (min) (median (IQR)) | 200 | 24 (15–35) | 180 | 24 (15–35) | 20 | 24 (18–40) | 0.93 |
*Number of patients with no missing data.
ASPECTS, Alberta Stroke Program Early CT Score; ICA, internal carotid artery; IV t-PA, intravenous tissue plasminogen activator; M1, proximal segment of the middle cerebral artery; M2, distal segment of the middle cerebral artery; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS, National Institutes of Health Stroke Scale.